Can ruxolitinib help CMML patients who also have connective tissue disease?

Ruxolitinib combined with azacytidine has shown promise for patients who have connective tissue disease alongside chronic myelomonocytic leukemia (CMML). This approach targets both the autoimmune inflammation and the cancerous blood cell growth. One documented case involved a patient with severe anemia and recurrent fever who improved significantly after starting this dual-target treatment.

What the research says

In a detailed case report, a 52-year-old man was initially treated for connective tissue disease but continued to suffer from fever and severe anemia. His condition was eventually diagnosed as CMML with myelofibrosis. Doctors then used a regimen of azacytidine plus ruxolitinib ¹. This combination therapy successfully relieved his fever and systemic symptoms, corrected the high monocyte counts typical of CMML, and markedly improved his anemia and low platelet counts ¹.

Other research focuses on how different treatments affect survival in advanced CMML, though it does not specifically detail ruxolitinib for connective tissue cases ². Studies using decitabine found that keeping white blood cell and monocyte counts low after treatment was linked to longer survival ². Another case study highlights that CMML can sometimes be mistaken for immune thrombocytopenia (ITP) before the cancer is found, emphasizing the need for careful monitoring of blood counts and bone marrow tests ³.

What to ask your doctor

• Is the combination of azacytidine and ruxolitinib an option for my specific case of CMML and connective tissue disease?
• How will we monitor my fever, anemia, and monocyte levels while on this dual-target treatment?
• What are the potential side effects of using ruxolitinib alongside other immunosuppressants for my autoimmune condition?
• Are there clinical trials available for CMML patients who also have connective tissue disorders?